Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 44th annual JPMorgan Healthcare Conference. My name is Tess Romero, and I'm one of the senior biotech analysts here at JPMorgan.
Our next presenting company is Agios, and presenting on behalf of the company, we have CEO, Brian Goff. Brian, over to you.
All right. Thank you, Tess, and good morning, everybody. It is great to be back at JPMorgan, and I'm really excited to share our outlook for 2026 and why we're so excited about the path forward for Agios.
Before I get started, I'll just remind everybody that I will be making forward-looking statements, so I'd encourage you to take the time to read through the details of this slide. This is a pivotal moment for Agios. We're at a major growth inflection point, and it really comes down to three key components that I'll talk about this morning. The first is that our PK activator, pyruvate kinase activator franchise, is proving itself to advance as the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
